Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Xpress
A Veterans Health Administration analysis of 4,890 men with metastatic hormone-sensitive prostate cancer found that achieving a PSA level below 0.2 ng/mL within 9 months was associated with improved survival. The retrospective findings support a threshold previously identified in clinical trials.
Hematology/Oncology August 18th 2026
Cardiology Advisor
Patients with primary tricuspid regurgitation had longer survival than those with secondary or lead-associated TR in a 12,899-patient Mayo Clinic retrospective cohort.
Cardiology May 5th 2026
JCO Clinical Cancer Informatics (JCO CCI)
The study introduced an ML-based, tunable risk stratification strategy tailored for AML patients treated with venetoclax plus azacitidine. By addressing real-world data limitations and incorporating diverse diagnostic features, the approach enables more accurate and adaptable prognostic modeling than traditional systems, supporting personalized treatment decisions and broader clinical applicability.
Hematology/Oncology March 30th 2026
Fox Chase Cancer Center
Statistical models incorporating individual clinical and tumor characteristics showed superior accuracy when validated against standardized clinical trial data compared to retrospective prediction tools.
Oncology, Medical June 24th 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS